"What's the difference between a puma and a lynx? Who cares . . . Puma's Nerlynx is approved."
Research note from Cory Kasimov, analyst, JP Morgan, on the FDA approval of Puma Biotechnology Inc.'s breast cancer drug, Nerlynx (neratinib), marking the first treatment designated as an extended adjuvant therapy in patients with early stage, HER2-positive disease

"Reduction of discoindin domain receptor expression in several models of Parkinson's and Alzheimer's disease allows nerve cells to switch on autophagy to clear toxic proteins and help the brain insulate itself from circulating inflammatory cells. This led to cognitive improvements in our animal models."
Charbel Moussa, of Georgetown Medical Center's Laboratory of Dementia and Parkinsonism, speaking at the Alzheimer's Association International Conference on the growing body of in vitro, animal and more recently clinical research that is pointing to the potential for tyrosine kinase inhibitors, which have established their therapeutic value in cancer, to be repurposed as treatments for Alzheimer's and other neurodegenerative diseases

"We've been doing these structured deals for about nine years, and what we've found from experience is that they tend to be larger deals and they have great returns. We wanted to be able to participate commensurately, and that's why the larger fund."
Emmett Cunningham, managing director, Clarus Ventures, on its new $910 million Clarus IV LP fund